Anebulo Pharmaceuticals, Inc. · OTC:ANEB

Anebulo Pharmaceuticals — IPO Roadshow (April 2021)

26 slides from Anebulo Pharmaceuticals's IPO roadshow presentation, Apr 26, 2021

  1. Slide 1: Management Presentation April 2021

    Slide 1: Management Presentation April 2021

    Management Presentation April 2021

  2. Slide 2: Free Writing Prospectus Statement

    Slide 2: Free Writing Prospectus Statement

    Free Writing Prospectus Statement This presentation highlights basic information about us and the offering to which this presentation relates. Because it is a summary, it does not contain all of the information that you should consider before investing in our securities. Anebulo Pharmaceuticals, Inc

  3. Slide 3: Cautionary Note Regarding Forward-Looking Statements

    Slide 3: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Litigation Securities Litigation Reform Act of 1995. Those statements include, but are not limited to, statements with respect to

  4. Slide 4: The Offering

    Slide 4: The Offering

    The Offering Issuer Anebulo Pharmaceuticals, Inc. Transaction Type Initial Public Offering of Common Stock Anticipated NASDAQ Symbol: ANEB Shares Offered: 3,000,000 (100% Primary) IPO Price Range: $6.00 - $8.00 Overallotment Option: 15% (100% Primary) 22NW, LP, an entity controlled by Aron R. Englis

  5. Slide 5: Investment highlights

    Slide 5: Investment highlights

    Investment highlights Addressing unmet medical need to treat cannabinoid overdose, a large and growing market • No product is approved for this indication and no other compound is further along in clinical testing • In 2018, ~1.7 million emergency department visits in U.S., growing 15% annually • Le

  6. Slide 6: Leadership

    Slide 6: Leadership

    Leadership Management Dan Schneeberger, MD, MBA Rex Merchant, CFA Linda Klumpers, PhD Chief Executive Officer Chief Financial officer Chief Scientific Officer McKinsey & Co., JFL Capital Management, JFL Capital Management, Clinical Pharmacologist, specialized in clinical ADAR1 Capital Management Wes

  7. Slide 7: ANEB-001 for Cannabinoid Overdose

    Slide 7: ANEB-001 for Cannabinoid Overdose

    ANEB-001 for Cannabinoid Overdose 7

  8. Slide 8: Cannabis-associated ED visits are frequent and rapidly growing

    Slide 8: Cannabis-associated ED visits are frequent and rapidly growing

    Cannabis-associated ED visits are frequent and rapidly growing Number of annual cannabis-associated emergency department visits in the United States, 2006-2018 Growth of cannabis- Outside of NEDS (estimated) 1,741,747 associated emergency 1,600,000 department visits has Captured in NEDS 1,400,000 +1

  9. Slide 9: Significant unmet medical need

    Slide 9: Significant unmet medical need

    Significant unmet medical need “Have had several pediatric Company-sponsored survey of 27 U.S. emergency room physicians patients require intubation (November 2020) secondary to cannabis overdose and would make a large impact on their care.” On average, the physicians saw 10.5 patients with cannabis

  10. Slide 10: Marijuana legalization is increasing

    Slide 10: Marijuana legalization is increasing

    Marijuana legalization is increasing Legalized Medical and Decriminalized Medical Decriminalized Fully illegal Marijuana is legal for recreational use in 16 states and is legal for medical use in 35 states Since 2012, recreational marijuana has gone from legal in no states to legal in 16 states 4 st

  11. Slide 11: Legalization drives ED visits

    Slide 11: Legalization drives ED visits

    Legalization drives ED visits Cannabis-Attributable ED Visits Four-year study at University of Colorado Hospital Edible Inhalable • Marijuana-related ED visits tripled after Colorado became the first U.S. state to allow n= recreational sales • 2-3 patients per day presented with severe 750 vomiting,

  12. Slide 12: Potency of edibles tends to be deceiving

    Slide 12: Potency of edibles tends to be deceiving

    Potency of edibles tends to be deceiving Manufactured as familiar products to consumers, including candy bars or gummy snacks • Consumers often approach cannabis edibles with the same serving size expectations as non-cannabis products • Cannabis candy bar may contain 4x or more times a safe dose of

  13. Slide 13: Synthetic cannabinoids are a growing problem

    Slide 13: Synthetic cannabinoids are a growing problem

    Synthetic cannabinoids are a growing problem Synthetic cannabinoids (commonly These drugs have serious potential side referred to as “spice” or “K2”) are the effects including seizures, renal failure fastest-growing class of psychoactive and death, and were responsible for a drug worldwide. well-pub

  14. Slide 14: A promising solution for treating cannabinoid overdose

    Slide 14: A promising solution for treating cannabinoid overdose

    A promising solution for treating cannabinoid overdose ANEB-001 • CB1 antagonist. Blocks the effect of THC at the CB1 receptor. Well understood pharmacology. • Oral bioavailability. ANEB-001 is administered as an oral treatment in the form of a pill, capsule or tablet. • Rapid absorption. We believe

  15. Slide 15: Well understood pharmacology de-risks clinical development

    Slide 15: Well understood pharmacology de-risks clinical development

    Well understood pharmacology de-risks clinical development THC THC ANEB-001 is a competitive antagonist at the human CB1 CB1 Receptor receptor with an affinity of ANEB-001 Cell membrane Cell membrane CB1 Receptor 0.6nM Effects Effects Good bioavailability and brain penetration (brain:plasma Feeling

  16. Slide 16: ANEB-001 is rapidly absorbed and reaches potentially therapeutic blood levels

    Slide 16: ANEB-001 is rapidly absorbed and reaches potentially therapeutic blood levels

    ANEB-001 is rapidly absorbed and reaches potentially therapeutic blood levels within 30 minutes Single Ascending Dose PK • n=18, 6 subjects/dose, 4 at 150mg 1400 • ANEB-001 is: 1200 – Rapidly absorbed 1000 ANEB-001 ng/ml – Extensively protein bound 800 – No cytochrome inhibition 600 • No serious adv

  17. Slide 17: Phase 2 proof-of-concept trial: design

    Slide 17: Phase 2 proof-of-concept trial: design

    Phase 2 proof-of-concept trial: design • n=100, 25 healthy volunteers (HV) will be randomized to each of 3 doses Cohort 1: of ANEB-001 or placebo 50mg • All HVs will receive 10mg THC orally + placebo or drug • Endpoints: – 1° inhibition of primary central nervous system effect of THC Cohort 2: 100mg

  18. Slide 18: Development plan

    Slide 18: Development plan

    Development plan H1 2022 Readout Life- Cycle management Proof-of-Concept Pivotal Program* New Drug Application 5+ years of market exclusivity • 100 healthy • Design to be • Exploration of • Method of use patents filed volunteers determined strategic options for • Upside if additional IP • THC + 3 do

  19. Slide 19: Growth strategy

    Slide 19: Growth strategy

    Growth strategy • Develop and commercialize ANEB-001 antagonist in the U.S. • Explore strategic collaborations to commercialize ANEB-001 • Ensure capital-efficient business model by outsourcing clinical research and data management • Introduce product candidate extensions - Non-oral formulation of A

  20. Slide 20: Strategic Implementation

    Slide 20: Strategic Implementation

    Strategic Implementation • Continued lean corporate structure with low burn rate (overhead ~$3M/year) • Phase 2 proof-of-concept trial to commence in Q4 2021 and results expected H1 2022 (Cost: ~$2M) • Continued strengthening of IP portfolio • Additional development of formulations/indications for A

  21. Slide 21: In summary

    Slide 21: In summary

    In summary Addressing unmet medical need in large and growing market, with cannabinoid overdose becoming an increasingly widespread health issue ANEB-001 is a de-risked asset with well understood mechanism of action as a CB1 antagonist Rapid path to proof-of-concept with Phase 2 study commencing in

  22. Slide 22: Appendix

    Slide 22: Appendix

    Appendix 22

  23. Slide 23: ED physicians are likely to prescribe a drug with our target product profile

    Slide 23: ED physicians are likely to prescribe a drug with our target product profile

    ED physicians are likely to prescribe a drug with our target product profile and believe that it would reduce the need for supportive medication We sponsored a survey of 27 Emergency room physicians throughout the United States Assuming you have a cannabinoid antagonist available that will reverse c

  24. Slide 24: Preclinical proof of concept: ANEB-001 reverses THC-induced hypolocomotion in mice

    Slide 24: Preclinical proof of concept: ANEB-001 reverses THC-induced hypolocomotion in mice

    Preclinical proof of concept: ANEB-001 was able to reverse THC-induced hypolocomotion in mice Effect of ANEB-001 on THC-induced hypolocomotion 1000 P<0.01 800 P<0.01 TOTAL ACTIVE TIME (s) 600 400 200 0 veh/veh veh/THC ANEB-001/THC 30mg/kg po 30 min pre-test, total active time over 15 minutes in C57

  25. Slide 25: Phase 1 Part B data in obese patients: weight loss

    Slide 25: Phase 1 Part B data in obese patients: weight loss

    Phase 1 – Part B data in obese patients shows drug is on target: weight loss Change from Baseline (Day-1) in Body Weight for Individual Days for All Treatments (Efficacy Population) Placebo OD (D1-D14) 200 mg ANEB-001 (D1)/50mg OD ANEB-001 (D2-D14) 50 mg ANEB-001 (D1)/5mg OD ANEB-001 (D2-D14) 100 mg

  26. Slide 26: Phase 1 Part B data in obese patients: reduced test meal energy intake

    Slide 26: Phase 1 Part B data in obese patients: reduced test meal energy intake

    Phase 1 - Part B data in obese patients shows drug is on target: reduced test meal energy intake Test Meal Energy Intake D-1 D7 D14 2,500 2,000 Mean Energy Intake (kcal) 1,500 1,000 500 0 Placebo OD 50:5mg OD 75:15mg OD 200:50mg OD 100mg 26

Source: company website

More decks from Anebulo Pharmaceuticals, Inc.

All 5 Anebulo Pharmaceuticals decks